Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine

Sanofi is reviewing its late-stage pipeline, expanding its business-development focus and seeking to rebuild early-stage research productivity under new Chief Scientific Officer Mike Quigley. The comments signal a strategic effort to strengthen the company’s drug-development pipeline, but provide no financial targets, clinical-data updates or specific transaction plans.